SI2838539T1 - Estrogenski derivati za uporabo pri zdravljenju nevroloških motenj - Google Patents

Estrogenski derivati za uporabo pri zdravljenju nevroloških motenj

Info

Publication number
SI2838539T1
SI2838539T1 SI201330825T SI201330825T SI2838539T1 SI 2838539 T1 SI2838539 T1 SI 2838539T1 SI 201330825 T SI201330825 T SI 201330825T SI 201330825 T SI201330825 T SI 201330825T SI 2838539 T1 SI2838539 T1 SI 2838539T1
Authority
SI
Slovenia
Prior art keywords
treatment
neurological disorders
estrogenic derivatives
estrogenic
derivatives
Prior art date
Application number
SI201330825T
Other languages
English (en)
Inventor
Jean-Michel Foidart
Ekaterine Tskitishvili
Original Assignee
Universite De Liege
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite De Liege filed Critical Universite De Liege
Publication of SI2838539T1 publication Critical patent/SI2838539T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
SI201330825T 2012-04-19 2013-04-08 Estrogenski derivati za uporabo pri zdravljenju nevroloških motenj SI2838539T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12164741.6A EP2653163A1 (en) 2012-04-19 2012-04-19 Estrogenic components for use in the treatment of neurological disorders
PCT/EP2013/057279 WO2013156329A1 (en) 2012-04-19 2013-04-08 Estrogenic components for use in the treatment of neurological disorders.
EP13714917.5A EP2838539B1 (en) 2012-04-19 2013-04-08 Estrogenic derivatives for use in the treatment of neurological disorders.

Publications (1)

Publication Number Publication Date
SI2838539T1 true SI2838539T1 (sl) 2017-12-29

Family

ID=48050711

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330825T SI2838539T1 (sl) 2012-04-19 2013-04-08 Estrogenski derivati za uporabo pri zdravljenju nevroloških motenj

Country Status (19)

Country Link
US (1) US9238035B2 (sl)
EP (2) EP2653163A1 (sl)
JP (1) JP6139662B2 (sl)
CN (1) CN104379148B (sl)
AU (1) AU2013248481B2 (sl)
CA (1) CA2869902C (sl)
CY (1) CY1119603T1 (sl)
DK (1) DK2838539T3 (sl)
ES (1) ES2647111T3 (sl)
HR (1) HRP20171627T1 (sl)
HU (1) HUE034902T2 (sl)
LT (1) LT2838539T (sl)
NO (1) NO2838539T3 (sl)
PL (1) PL2838539T3 (sl)
PT (1) PT2838539T (sl)
RS (1) RS56595B1 (sl)
RU (1) RU2627846C2 (sl)
SI (1) SI2838539T1 (sl)
WO (1) WO2013156329A1 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2714710T (pt) 2011-06-01 2016-07-12 Estetra Sprl Processo para a produção de intermediários de estetrol
CA2835979C (en) 2011-06-01 2018-05-01 Estetra S.A. Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US11638745B2 (en) * 2015-05-20 2023-05-02 University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education Method to improve neurologic outcomes in temperature managed patients
KR102664563B1 (ko) 2015-06-18 2024-05-09 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 에스테트롤 성분을 함유하는 구강분해성 투여 단위
EP3310346B1 (en) 2015-06-18 2021-03-24 Estetra SPRL Orodispersible tablet containing estetrol
SI3310333T1 (sl) * 2015-06-18 2020-08-31 Estetra Sprl Orodisperzibilna enota odmerka, ki vsebuje komponento estetrola
CA2988485A1 (en) * 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN107260712A (zh) * 2017-06-22 2017-10-20 中国人民解放军第三军医大学 奥培米芬在制备促进髓鞘形成和再生的药物中的应用
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
CN113243332B (zh) * 2020-02-07 2023-07-28 上海市东方医院(同济大学附属东方医院) 一种广泛脑区神经元树突发育障碍动物模型的制备与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
CA2489271C (en) * 2002-06-11 2011-12-06 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
AU2003274943A1 (en) 2002-06-11 2003-12-22 Pantarhei Bioscience B.V. Use of estetrol and analogues for treating or preventing cardiovascular pathologies, in particular atherosclerosis
JP2009510084A (ja) * 2005-09-26 2009-03-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己免疫及び神経変性疾患及び障害のためのエストリオール療法
WO2007081206A1 (en) * 2006-01-09 2007-07-19 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
WO2008156365A1 (en) * 2007-06-21 2008-12-24 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
AU2008325211B2 (en) * 2007-11-06 2014-11-13 Signal Coordinating Therapy, Inc. Compositions and methods for treating Parkinson's disease and related disorders
CN101884638B (zh) * 2010-07-09 2011-11-09 中山大学 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用

Also Published As

Publication number Publication date
EP2653163A1 (en) 2013-10-23
EP2838539A1 (en) 2015-02-25
RU2627846C2 (ru) 2017-08-14
NO2838539T3 (sl) 2018-01-13
DK2838539T3 (da) 2017-11-27
AU2013248481B2 (en) 2017-02-16
US20150133419A1 (en) 2015-05-14
HRP20171627T1 (hr) 2017-12-01
RS56595B1 (sr) 2018-02-28
PT2838539T (pt) 2017-11-15
AU2013248481A1 (en) 2014-10-30
LT2838539T (lt) 2017-11-27
CA2869902C (en) 2019-07-02
CA2869902A1 (en) 2013-10-24
HUE034902T2 (hu) 2018-03-28
WO2013156329A1 (en) 2013-10-24
CN104379148A (zh) 2015-02-25
ES2647111T3 (es) 2017-12-19
PL2838539T3 (pl) 2018-01-31
CN104379148B (zh) 2017-08-25
EP2838539B1 (en) 2017-08-16
RU2014145800A (ru) 2016-06-10
US9238035B2 (en) 2016-01-19
JP2015514731A (ja) 2015-05-21
JP6139662B2 (ja) 2017-05-31
CY1119603T1 (el) 2018-04-04

Similar Documents

Publication Publication Date Title
LT2838539T (lt) Estrogeniniai dariniai, skirti naudoti neurologinių sutrikimų gydymui
IL238180A0 (en) Compounds of carbohydrates with glucose for the treatment of diabetic nephropathy and related disorders
GB2492487B (en) Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
SG10201912275YA (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders
PL3811943T3 (pl) Związek do stosowania w leczeniu zaburzeń oczu
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
HRP20190038T1 (hr) Derivati pantotenata namijenjeni liječenju neuroloških poremećaja
IL235127A (en) Hpn-100 for use in the treatment of nitrogen-related diseases
HK1192726A1 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
ZA201306613B (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
HK1219224A1 (zh) 角結膜病症的治療劑
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
IL237912A0 (en) History of dihydro-6-azaphenylene for the treatment of the central nervous system, oncological diseases and similar disorders
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
EP2958570A4 (en) THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PERIANAL DISORDERS
AU2012900788A0 (en) Combination treatment for rheumatic disorders